The characteristics of BCR‐CDR3 repertoire in COVID‐19 patients and SARS‐CoV‐2 vaccinated volunteers
Journal of Medical Virology · 2024-03 · 96 (3)
DOI: 10.1002/jmv.29488 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medical Virology, online erschienen am 28.02.2024. Verfasst von Jiaping Xiao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Center of Immunomolecular Engineering, Innovation & Practice Base for Graduate Students Education, Zunyi Medical University…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 82 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guizhou Provincial Hundred Level Talent Fund.
Abstract (Originalsprache)
The global COVID‐19 pandemic has caused more than 1 billion infections, and numerous SARS‐CoV‐2 vaccines developed rapidly have been administered over 10 billion doses. The world is continuously concerned about the cytokine storms induced by the interaction between SARS‐CoV‐2 and host, long COVID, breakthrough infections postvaccination, and the impact of SARS‐CoV‐2 variants. BCR‐CDR3 repertoire serves as a molecular target for monitoring the antiviral response “trace” of B cells, evaluating the effects, mechanisms, and memory abilities of individual responses to B cells, and has been successfully applied in analyzing the infection mechanisms, vaccine improvement, and neutralizing antibodies preparation of influenza virus, HIV, MERS, and Ebola virus. Based on research on BCR‐CDR3 repertoire of COVID‐19 patients and volunteers who received different SARS‐CoV‐2 vaccines in multiple laboratories worldwide, we focus on analyzing the characteristics and changes of BCR‐CDR3 repertoire, such as diversity, clonality, V&J genes usage and pairing, SHM, CSR, shared CDR3 clones, as well as the summary on BCR sequences targeting virus‐specific epitopes in the preparation and application research of SARS‐CoV‐2 potential therapeutic monoclonal antibodies. This review provides comparative data and new research schemes for studying the possible mechanisms of differences in B cell response between SARS‐CoV‐2 infection or vaccination, and supplies a foundation for improving vaccines after SARS‐CoV‐2 mutations and potential antibody therapy for infected individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Center of Immunomolecular Engineering, Innovation & Practice Base for Graduate Students Education, Zunyi Medical University, Zunyi, Guizhou, China.
- Fushun People's Hospital, Zigong, Sichuan, China.
ORCID-Profile: Xinsheng Yao
Förderung
- National Natural Science Foundation of China
- Guizhou Provincial Hundred Level Talent Fund
Zitieren
APA
Xiao, J., Luo, Y., Li, Y., & Yao, X. (2024). The characteristics of BCR‐CDR3 repertoire in COVID‐19 patients and SARS‐CoV‐2 vaccinated volunteers. Journal of Medical Virology, 96(3). https://doi.org/10.1002/jmv.29488
Vancouver
Xiao J, Luo Y, Li Y, Yao X. The characteristics of BCR‐CDR3 repertoire in COVID‐19 patients and SARS‐CoV‐2 vaccinated volunteers. Journal of Medical Virology. 2024;96(3). doi:10.1002/jmv.29488
BibTeX
@article{Xiao2024,
author = {Xiao, Jiaping and Luo, Yan and Li, Yangyang and Yao, Xinsheng},
title = {The characteristics of BCR‐CDR3 repertoire in COVID‐19 patients and SARS‐CoV‐2 vaccinated volunteers},
journal = {Journal of Medical Virology},
year = {2024},
volume = {96},
number = {3},
doi = {10.1002/jmv.29488}
}
EUVIMED